^
Association details:
| Biomarker: | HER-2 I655V |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Irene (pyrotinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Efficacy and safety of pyrotinib in advanced lung adenocarcinoma with HER2 mutations: a multicenter, single-arm, phase II trial
Published date:
02/01/2022
Excerpt:
In this multicenter, single-arm, phase II trial, stage IIIB-IV NSCLC patients harboring HER2 mutations, as determined using next-generation sequencing, were enrolled and treated with pyrotinib at a dose of 400 mg/day....In addition, among the three patients with TMD mutations, the two patients carrying V658E substitution showed PFS of 2.9–5.6 months and OS of 5.3–5.6 months, while the patient harboring I655V had PFS and OS of 0.8 and 1.13 months, respectively…
DOI:
https://doi.org/10.1186/s12916-022-02245-z
